Trump’s boasting overshadows supply deal for COVID-19 drugsPresident Trump’s big agreement with a new US drugmaker to supply drugs for COVID-19 has been overshadowed by Share XTrump’s boasting overshadows supply deal for COVID-19 drugshttps://pharmaphorum.com/news/hopped-up-on-hydroxychloroquine-trump-signs-354m-deal-for-covid-19-drug-supply/
Antitrust delay scuppers Novartis’ $1bn generics sale to AurobindoNovartis has called off the sale of two US generics businesses to India’s Aurobindo Pharma, part of a Share XAntitrust delay scuppers Novartis’ $1bn generics sale to Aurobindohttps://pharmaphorum.com/news/antitrust-delay-scuppers-novartis-1bn-generics-sale-to-aurobindo/
Amarin hit hard as generics loom for fish oil drug VascepaGeneric drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that Share XAmarin hit hard as generics loom for fish oil drug Vascepahttps://pharmaphorum.com/news/amarin-hit-hard-as-generics-loom-for-fish-oil-drug-vascepa/
Biogen claims victory in patent dispute with Mylan over MS drug TecfideraShares in Biogen are on the rise after the company successfully defended its blockbuster multiple sclerosis drug Tecfidera Share XBiogen claims victory in patent dispute with Mylan over MS drug Tecfiderahttps://pharmaphorum.com/news/biogen-claims-victory-in-patent-dispute-with-mylan-over-ms-drug-tecfidera/
Merck to spin old drugs into ‘NewCo’ focused on generics, women’s healthMerck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving Share XMerck to spin old drugs into ‘NewCo’ focused on generics, women’s healthhttps://pharmaphorum.com/news/merck-to-spin-old-drugs-into-newco-focused-on-generics-womens-health/
Lilly claims another victory in Alimta patent defenceEli Lilly ended 2019 with a win in its long-running legal battle to prevent generics of its big-selling Share XLilly claims another victory in Alimta patent defencehttps://pharmaphorum.com/news/lilly-claims-another-victory-in-alimta-patent-defence/
Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
Takeda nets $660m from product selloff to Germany’s StadaTakeda has divested another block of products it views as lying outside its main focus, selling various drugs Share XTakeda nets $660m from product selloff to Germany’s Stadahttps://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/
Mylan up on OK for generic of Lilly’s $2bn cancer drug AlimtaShares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli Share XMylan up on OK for generic of Lilly’s $2bn cancer drug Alimtahttps://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/
